Effect of ditazole, an inhibitor of platelet aggregation, on a metastasizing tumour in mice. by Mussoni, L. et al.
Br. J. Cancer (1978) 37, 126.
Short Communication
EFFECT OF DITAZOLE, AN INHIBITOR OF PLATELET
AGGREGATION, ON A METASTASIZING TUMOUR IN MICE
L. AMUSSONI,* A. POGGI, G. DE GAETANO AND M. B. DONATI
From the Laboratory for Haemostasis and Thrombosis Research, Istituto di Ricerche Farmacologiche
"Mario Negri", Via Eritrea, 62-20157 Milan, Italy
Received 1 August 1977
IT has been suggested that platelets may
play an important role in the development
of cancer metastasis; indeed, platelet
aggregates around tumour cells would
facilitate their arrest by the small vessels
and their subsequent extravascular migra-
tion (Gasic, Gasic and Stewart, 1968;
Hilgard, 1973; Wood, 1974). This hypo-
thesis has been further supported by the
observation that drugs inhibiting platelet
aggregation, such as acetylsalicylic acid
and indomethacin, decreased cancer dis-
semination and metastasis formation in
some experimental tumours (Gasic, Gasic
and Murphy, 1972; Kolenich, Mansour and
Flynn, 1972; Li Volsi, 1973).
Our group has recently shown that
ditazole, a new non-steroidal anti-
inflammatoryagentwithinhibitoryactivity
against platelet aggregation, also inhibits
thefall inplatelet countinduced in mice by
i.v. injection of cells from the Lewis lung
carcinoma (3LL) (Mussoni et al., 1977).
This is an experimental tumour syngeneic
with C57BL/6 mice, which metastasizes
selectively to the lungs when implanted
i.m. (Karrer, Humphreys and Goldin,
1967; Simpson-Herren and Lloyd, 1970).
Although platelet consumption seems not
to occur during development of this
tumour after i.m. implantation (Poggi et
al., 1977), an interaction between cancer
cells and platelets in this model (at least in
the early phases of tumour development)
cannot be excluded. The aim of this study
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was therefore to investigate whether
ditazole treatment would affect thegrowth
and metastatic spread of 3LL cells.
Animals, materials and methods used in
this study have been previously described
(Poggi et al., 1976, 1977).
Four experiments were performed.
Exp. A.-Groups of 20 animals were
treated daily with 3 different doses of
ditazole: 100, 200, or 400 (200 every 12 h)
mg/kg body wt. The drug was suspended
in 0.5% carboxymethylcellulose (CMC)
and given orally, from 1 h before tumour
implantationuntil thedeathoftheanimals.
Control tumour-bearing animals were
treated with CMC. Tumour and metastases
were measured in each animal after its
spontaneous death.
Exp. B.-20 pairs of 3LL-bearing mice
were randomly allocated at the beginning
of the experiment to receive either CMC
alone or ditazole (200 mg/kg twice daily).
When either animal of the pair died, its
counterpart was killed.
Exp. C.-A group of 40 mice was im-
planted i.m. with 3LL tumour; after 11
days the tumour-bearing leg was surgically
removed; the animals were then randomly
allocated to receive either CMC alone or
ditazole (200 mg/kg, twice daily) until each
animal died spontaneously.
Exp. D.-After surgical removal of the
primary tumour as in Exp. C., 15 pairs of
mice were randomly allocated to receive
either CMC alone or ditazole (200 mg/kg
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TABLE-Effect of Ditazole Treatment Alone (Exp. A, B) or in Combination withSurgical
Removal of the Tumour-bearing Leg (Exp. C, D) on 3LL Tumour and Metastases.
Results Obtained at Spontaneous Death of the Animals (Exp. A, C) or at Death of one
Component of Preconstituted Pairs of Control and Treated Mice (Exp. B, D) are ex-
pressed as Mean ± s.e.
Surviva1 tin
Experiment TreatmeInt (days)
A CMC 29 5±15
Ditazolet 26 4±22
Ditazolet 26 7±1i 6
Ditazole§ 24-7±3i 5
B CMC 2 ±
Ditazole§ 239±08
C Surgery+CMC 30 5±3i 5
Surgery+ 32 5±009
Ditazole§
D Surgery+CMC
Surgery+ 28 6±3-0
Ditazole§
t 100 mg/kg daily by mouth.
1 200 mg/kg daily by mouth.
§ 200 mg/kg twice daily by mouth.
*P<O-05.
** P<o.0l.
twice daily): when either animal of the
pair died, its counterpart was killed.
Statistical evaluation ofthe results used
the Dunnett test (Dunnett, 1955) for
Experiment A and Student's t test for
paired data for the 3 other experiments.
The effects of different doses of ditazole
on the mean survival time and on some
parameters of 3LL growth and metastasis
are reported in the Table (Exp. A).
All the parameters considered appeared
to decrease with increasing doses of the
drug. In particular, the metastatic para-
meters were significantly reduced in anim-
als given a single daily dose of 200 mg
ditazole/kg. However, the mean survival
time of the animals was also shorter in
treated animals, although not significantly
so. To evaluate whether the inhibitory
effect of the drug on metastasis could be
due to the reduced survival of treated
animals, further experiments were per-
formed using pairs of control and treated
animals. In this case, the mean survival
times of the groups of animals were
identical (Exp. B). No statistically signifi-
cant differences were found between con-
trol and ditazole-treated mice for any of
ne Tumour wt.
(g)
6 4±0*5
6 5±0 7
5 7±0 5
5 6±0 5
8-9±0*7
7-4±0 5*
Lung wt.
(mg)
513±50
468±70
367±30**
332±30**
397±23
449±56
551±12
892+ 111
No. of
Metastases
24 3±2 6
18 6±4 1
17 3±1 8
15 1±2 4
18 9±2 4
21*5±3 2
19 0±4 5
270±2*5
- 474±66 10 9±4-4 173±61
628±59 16 5±3-3 293±69
the parameters evaluated, except for the
primary tumour weight, which was signifi-
cantly lower in treated animals.
In Experimnents C and D the primary
tumour was removed by surgery 11 days
after its implantation and treatment with
either ditazole or placebo started there-
after. Animals were then evaluated either
at spontaneous death (Exp. C) or at death
of one component ofthe pairs (Exp. D). In
both experiments, a marked, though not
statistically significant, increase ofnumber
and weight of metastasis was observed in
ditazole-treated mice.
The present study was based on the
assumption that blood platelet aggregation
by cancer cells might be of importance in
the pathogenesis of metastasis in experi-
mental tumours (Hilgard, 1973; Gasic et
al., 1968; Wood, 1974). The results
obtained indicate that, at doses inhibiting
platelet aggregation in mice (Mussoni etal.,
1977) ditazole did not significantly influ-
ence spontaneous metastasis formation in
the 3LL tumour. Previous studies
(Mussoni et al., 1977) had shown that
ditazole effectively protected animals from
the acute thrombocytopenia induced by
Metastasis wt.
(mg)
178±26
134±44
112±26*
77±29**
126±29
217±55
391±31
682± 124
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i.v. injection of 3LL cells. This drug,
however, was unable to inhibit the
progressive thrombocytopenia developing
in mice transplanted i.m. with these cells.
This lack of protective effect of ditazole
was interpreted as a supporting argument
for the hypothesis that platelet production
might be defective in 3LL-bearing mice
(Poggi et al., 1976, 1977).
The present data indicate that normal
platelet function is not a prerequisite for
haematogenous metastasis in 3LL-bearing
mice. This is in agreementwithsomerecent
observations by Hilgard, Heller and
Schmidt (1976) who found that various
inhibitors of platelet aggregation had no
significant influence on spontaneous meta-
stasis of3LL tumour.
Using ICRF 159, a drug with antimeta-
static effect in the 3LL system, Atherton,
Busfield and Hellmann (1975) have shown
that antimetastatic effect and inhibition of
thrombus formation are not necessarily
linked. Hilgard et al. (1976) have observed
an increased number oflung colonies after
i.v. injection of 3LL cells into mice with
pharmacological suppression of platelet
function. Althoughthe differences between
our control and ditazole-treated animals
did not reach statistical significance, a
trend toward enhanced metastasis was
observed in several groups of treated
animals.
Very recently, Santoro, Philpott and
Jaffe (1976) provided evidence that the
pharmacological inhibition of prostaglan-
din biosynthesis stimulates cultured
tumour-cellgrowth,andthatprostaglandin
E2 inhibits tumour growth in mice bearing
B-16 melanoma. It is tempting to specu-
late that ditazole, which is also a powerful
inhibitor of prostaglandin biosynthesis
(Caprino et al., 1975; Patrono, Ciabattoni
and Grossi-Belloni, 1975) might favour the
development of 3LL by reducing the
availability of prostaglandins. Whether
such a mechanism would counteract the
possible beneficial effect of ditazole associ-
ated with inhibition ofplatelet aggregation
is at present unknown. Further studies
using platelet aggregation inhibitors not
affecting prostaglandin biosynthesis would
therefore seem appropriate.
The experienced assistanice of Nadia Polentarutti
was of invaluable help in performing some of the
experiments. Judith Baggot, Anna Mancini and
Graziella Scalvini helped us in preparing the manu-
script.
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Italy, through the courtesy of Professor Luciano
Caprino.
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